| MeSH term | MeSH ID | Detail |
|---|---|---|
| Bradycardia | D001919 | 13 associated lipids |
| Radiation Injuries | D011832 | 14 associated lipids |
| HIV Seropositivity | D006679 | 15 associated lipids |
| Synovitis | D013585 | 15 associated lipids |
| Bronchial Hyperreactivity | D016535 | 15 associated lipids |
| Encephalitis | D004660 | 15 associated lipids |
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Dermatomycoses | D003881 | 17 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Ischemia | D007511 | 18 associated lipids |
| Tuberculosis, Pulmonary | D014397 | 18 associated lipids |
| Peptic Ulcer | D010437 | 19 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Drug Hypersensitivity | D004342 | 20 associated lipids |
| Gastrointestinal Diseases | D005767 | 20 associated lipids |
| Myocardial Infarction | D009203 | 21 associated lipids |
| Helicobacter Infections | D016481 | 21 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Periodontitis | D010518 | 22 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- FEMS Immunol. Med. Microbiol. (1)
- J. Antimicrob. Chemother. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Jaup BH and Norrby A | Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7771426 |
| Gisbert JP et al. | Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? | 2005 | Am. J. Gastroenterol. | pmid:16128936 |
| Schaeverbeke T et al. | Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. | 2005 | Am. J. Gastroenterol. | pmid:16393213 |
| Mohar A et al. | Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. | 2002 | Am. J. Gastroenterol. | pmid:12385434 |
| De Francesco V et al. | Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia? | 2002 | Am. J. Gastroenterol. | pmid:12385470 |
| Chey WD and Wong BC | American College of Gastroenterology guideline on the management of Helicobacter pylori infection. | 2007 | Am. J. Gastroenterol. | pmid:17608775 |
| Uygun A et al. | Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. | 1999 | Am. J. Gastroenterol. | pmid:10520880 |
| Cremonini F et al. | Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. | 2002 | Am. J. Gastroenterol. | pmid:12425542 |
| Peterson WL et al. | Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. | 1993 | Am. J. Gastroenterol. | pmid:8237933 |
| Nista EC et al. | Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. | 2006 | Am. J. Gastroenterol. | pmid:16968503 |
| van Zanten SV and Thompson K | Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? | 2006 | Am. J. Gastroenterol. | pmid:16863548 |
| Rokkas T et al. | Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. | 2006 | Am. J. Gastroenterol. | pmid:16928256 |
| Sugimoto M et al. | Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. | 2000 | Am. J. Gastroenterol. | pmid:10685780 |
| Coelho LG et al. | Once-daily Helicobacter pylori treatment to family members of gastric cancer patients. | 2000 | Am. J. Gastroenterol. | pmid:10710099 |
| Pilotto A et al. | In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. | 2000 | Am. J. Gastroenterol. | pmid:10710100 |
| Watson JB and Moss SF | Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. | 2011 | Am. J. Gastroenterol. | pmid:22056576 |
| Zhou L et al. | A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. | 2014 | Am. J. Gastroenterol. | pmid:24642580 |
| Gisbert JP et al. | Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. | 2006 | Am. J. Gastroenterol. | pmid:16454825 |
| Ali' A et al. | A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. | 1999 | Am. J. Gastroenterol. | pmid:10445583 |
| Vakil N et al. | Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. | 1998 | Am. J. Gastroenterol. | pmid:9732920 |
| Chu KM et al. | A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. | 1998 | Am. J. Gastroenterol. | pmid:9732921 |
| Lamouliatte H et al. | Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. | 1998 | Am. J. Gastroenterol. | pmid:9732938 |
| Hsu PI et al. | A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. | 2005 | Am. J. Gastroenterol. | pmid:16279889 |
| Vakil N | Helicobacter pylori: factors affecting eradication and recurrence. | 2005 | Am. J. Gastroenterol. | pmid:16279890 |
| Sullivan B et al. | Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. | 2002 | Am. J. Gastroenterol. | pmid:12385435 |
| Chiba N | Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. | 1996 | Am. J. Gastroenterol. | pmid:8855737 |
| Gisbert JP et al. | Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. | 2008 | Am. J. Gastroenterol. | pmid:17764498 |
| Dohil R et al. | Effective 2-wk therapy for Helicobacter pylori disease in children. | 1997 | Am. J. Gastroenterol. | pmid:9040199 |
| Lerang F et al. | Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? | 1997 | Am. J. Gastroenterol. | pmid:9040200 |
| Odaka T et al. | Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. | 2002 | Am. J. Gastroenterol. | pmid:11922552 |
| Chey WD et al. | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. | 1997 | Am. J. Gastroenterol. | pmid:9317068 |
| Giannini E et al. | Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. | 2000 | Am. J. Gastroenterol. | pmid:11051345 |
| Ozmen MM and Johnson CD | Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? | 1995 | Am. J. Gastroenterol. | pmid:7661197 |
| Savarino V et al. | New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. | 1995 | Am. J. Gastroenterol. | pmid:7717343 |
| Trevisani L et al. | A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. | 1998 | Am. J. Gastroenterol. | pmid:9517646 |
| Hasegawa T et al. | Image of the month: Disseminated Nontuberculous Mycobacteriosis. | 2015 | Am. J. Gastroenterol. | pmid:26673493 |
| de Boer WA et al. | Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. | 1998 | Am. J. Gastroenterol. | pmid:9672338 |
| Calvet X et al. | Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. | 2005 | Am. J. Gastroenterol. | pmid:16086704 |
| Shaheen N and Grimm IS | Fulminant hepatic failure associated with clarithromycin. | 1996 | Am. J. Gastroenterol. | pmid:8607519 |
| Vakil N | Helicobacter pylori treatment: a practical approach. | 2006 | Am. J. Gastroenterol. | pmid:16542285 |
| Santander C et al. | Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. | 1996 | Am. J. Gastroenterol. | pmid:8759659 |
| Tursi A et al. | Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication. | 1996 | Am. J. Gastroenterol. | pmid:8759696 |
| Fuccio L et al. | Can sequential therapy for Helicobacter pylori eradication overcome clarithromycin resistance?: Data still do not support conclusions. | 2010 | Am. J. Gastroenterol. | pmid:20606668 |
| van der Wouden EJ et al. | One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. | 1998 | Am. J. Gastroenterol. | pmid:9707042 |
| Laine L et al. | Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. | 2000 | Am. J. Gastroenterol. | pmid:11151867 |
| Parasakthi N and Goh KL | Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. | 1995 | Am. J. Gastroenterol. | pmid:7872306 |
| Laine L et al. | Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. | 1997 | Am. J. Gastroenterol. | pmid:9399755 |
| Srinivasan R and Minocha A | Cure of Helicobacter pylori: a hidden curse? | 1997 | Am. J. Gastroenterol. | pmid:9399784 |
| Luther J et al. | Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. | 2010 | Am. J. Gastroenterol. | pmid:19755966 |
| Chey WD et al. | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. | 2017 | Am. J. Gastroenterol. | pmid:28071659 |